Hangzhou Diagens Biotechnology Co., Ltd. Class H

As of June 30, 2026, Hangzhou Diagens Biotechnology Co., Ltd. Class H carries a market capitalization of 27.53B, placing it among publicly traded companies globally. Its enterprise value stands at 26.84B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Hangzhou Diagens Biotechnology Co., Ltd. Class H has 88.88M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Hangzhou Diagens Biotechnology Co., Ltd. Class H maintains a current ratio of 7.32, meaning it holds 7.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Hangzhou Diagens Biotechnology Co., Ltd. Class H recorded 17,336.69 in income tax expense.

These figures are as of the close on October 22, 2026.

As of June 30, 2026, Hangzhou Diagens Biotechnology Co., Ltd. Class H holds 756.56M in cash and equivalents against 64.36M in total debt, resulting in a net debt position of -698.77M. Total book value stands at 895.79M, with working capital of 810.53M providing operational flexibility.